Free Trial
NASDAQ:NBTX

Nanobiotix (NBTX) Stock Price, News & Analysis

Nanobiotix logo
$3.39 -0.19 (-5.20%)
Closing price 04/2/2025 12:46 PM Eastern
Extended Trading
$3.23 -0.16 (-4.80%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nanobiotix Stock (NASDAQ:NBTX)

Key Stats

Today's Range
$3.35
$3.45
50-Day Range
$3.07
$4.16
52-Week Range
$2.76
$7.51
Volume
2,661 shs
Average Volume
21,351 shs
Market Capitalization
$159.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Moderate Buy

Company Overview

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Remove Ads

Nanobiotix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

NBTX MarketRank™: 

Nanobiotix scored higher than 52% of companies evaluated by MarketBeat, and ranked 513th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Nanobiotix has only been the subject of 1 research reports in the past 90 days.

  • Read more about Nanobiotix's stock forecast and price target.
  • Percentage of Shares Shorted

    0.02% of the float of Nanobiotix has been sold short.
  • Short Interest Ratio / Days to Cover

    Nanobiotix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nanobiotix has recently decreased by 68.60%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nanobiotix does not currently pay a dividend.

  • Dividend Growth

    Nanobiotix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.02% of the float of Nanobiotix has been sold short.
  • Short Interest Ratio / Days to Cover

    Nanobiotix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nanobiotix has recently decreased by 68.60%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Nanobiotix has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Nanobiotix this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Nanobiotix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.45% of the stock of Nanobiotix is held by insiders.

  • Percentage Held by Institutions

    Only 38.81% of the stock of Nanobiotix is held by institutions.

  • Read more about Nanobiotix's insider trading history.
Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

NBTX Stock News Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
See More Headlines

NBTX Stock Analysis - Frequently Asked Questions

Nanobiotix's stock was trading at $2.87 on January 1st, 2025. Since then, NBTX stock has increased by 18.3% and is now trading at $3.3940.
View the best growth stocks for 2025 here
.

Nanobiotix (NBTX) raised $95 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 6,500,000 shares at a price of $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO.

Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nanobiotix investors own include PayPal (PYPL), Sirius XM (SIRI), Ardelyx (ARDX), BridgeBio Pharma (BBIO), Cogent Communications (CCOI), Citius Pharmaceuticals (CTXR) and Datadog (DDOG).

Company Calendar

Today
4/02/2025
Next Earnings (Estimated)
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBTX
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+253.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$36.22 million
Price / Cash Flow
N/A
Book Value
($0.04) per share
Price / Book
-84.85

Miscellaneous

Free Float
45,507,000
Market Cap
$159.97 million
Optionable
Not Optionable
Beta
0.28
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:NBTX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners